|
Malaysian Journal of Medical Sciences
School of Medical Sciences, Universiti Sains Malaysia
ISSN: 1394-195X
Vol. 11, Num. 1, 2004, pp. 37-43
|
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004,
pp.37-43
REVIEW ARTICLE
What we Know About Molecular Genetics
of Central Nervous System (CNS) Tumours
in Malysia
Sarina Sulong, Abdul Aziz Mohamed Yusoff*, Norafiza Zainuddin,
Jafri Malin Abdullah*, Jain George Pannatil*, Hasnan Jaafar**, Mohd Nizam
Isa
Human Genome Center, Department of Neurosciences*, Department
of Pathology**, School of Medical Sciences, Universiti Sains Malaysia,
16150 Kubang Kerian, Kelantan, Malaysia
Correspondence : Prof. Dr. Jafri Malin Abdullah, MD, Dip. Cert. Specalization
Neurosurgery (Belgium), Psd. (Belgium), BACF, FRCF (Ed), FICF.
Department of Neuroscience,
School of Medical Sciences,
Universiti Sains Malaysia, Health Campus,
16150 Kubang Kerian, Kelantan, Malaysia
Code Number: mj04004
The new millennium has been regarded as a genomic era.
A lot of researchers and pathologists are beginning to understand the scientific
basis of molecular genetics and relates with the progression of the diseases.
Central nervous system (CNS) tumours are among the most rapidly fatal of
all cancers. It has been proposed that the progression of malignant tumours
may result from multi-step of genetic alterations, including activation of
oncogenes, inactivation of tumour suppressor genes and also the presence
of certain molecular marker such as telomerase activity. In this paper, we
review some recent data from the literature, including our own studies, on
the molecular genetics analysis in CNS tumours. Our studies have shown that
two types of tumour suppressor genes, p53 and PTEN were involved in the development
of these tumours but not in p16 gene among the patients from Hospital Universiti
Sains Malaysia (HUSM). Telomerase activity also has been detected in various
types of CNS tumours. Thus, it is important to assemble all data which related
to this study and may provide as a vital information in a new approach to
neuro-oncology studies in Malaysia.
Key words : molecular genetics, CNS tumours,
Malaysia
Introduction
Brain and spinal cord are the components of central nervous
system (CNS) and any tumour located near vital brain structures or sensitive
spinal cord nerves can seriously threaten health. However, spinal cord tumours
are less common than brain tumours (1). Primary CNS tumours such as gliomas
and meningiomas are named by the types of cells they contain, their location,
or both. Among the tumours of the CNS, gliomas are the biggest group. Astrocytomas,
the most common category of gliomas, are typically graded on a scale of I to
IV based on how quickly the cells are reproducing, as well as their potential
to invade nearby tissue. Grade I and II astrocytomas are the slowest growing
tumours, and are also called low-grade astrocytomas. Most meningiomas are slowly
growing benign tumours that histologically correspond to grade I of the World
Health Organization's classification of central nervous system tumours.
Over the last decade, a lot of ideas have been emerged about the genetic alterations
that occur in human cancers and how they contribute to the tumourigenesis
(2). Laboratory studies may play a vital role to investigate changes occurring
on a cellular level that will lead to better understanding of the biological
mechanisms involved in
brain tumor formation. Several specific tumour markers have been studied
to determine their importance in cancer research. Tumour suppressor genes are
one of the cancer-related genes that involved in malignant transformation (3).
Many tumour suppressor genes have been identified for example p53, PTEN, p16,
RB1, NF2 and APC, and inactivation of these genes have been reported in association
with carcinogenesis in human cancers. The ability to detect mutations in tumour
suppressor genes plays an important role in cancer diagnosis and prognosis (4).
Presence of
certain markers for cancer has also been proposed to be involved
in
human tumourigenesis such as telomerase enzyme. According
to the previous report, telomerase activity is detected in 61.7% of neuroepithelial
brain tumours; it is present in 0-20% of Grade I and II astrocytomas, 40% of
anaplastic astrocytomas and 72-100% of anaplastic glioblastoma multiforme (5).
Molecular staging using markers such as telomerase activity in combination
with other molecular markers may be particularly useful for early detection
of cancer (6). Basic scientists and clinicians must work together to prove
this strategy that can be applied in patient management and future treatment
of cancer.
Mutations in p53 gene
The best-studied molecular alteration in malignant (non-pilocytic)
astrocytic tumors is the inactivation of the tumor suppressor p53 gene. The
p53 gene is located on the short arm of chromosome 17 (17p13.1), encodes a
protein of 53 kD in molecular weight (393 amino-acid nuclear phosphoprotein.
It was first identified as a cellular protein in 1979 because it formed a tight
complex with the SV 40 large T antigen (7). Since then, p53 has been believed
to influence multiple aspects of cellular functions, including progression
through the cell control (8), DNA repair after radiation damage (9), genomic
stability (10), and the induction of programmed cell death, apoptosis (11).
p53 acts as a transcription factor to induce or repress the transcription of
multiple genes whose regulatory region through sequence-specific interaction
with DNA.
p53 is frequently found to be mutated in many types of human
cancer, including brain tumors (12,13). p53 mutations in adult astrocytoma
were first described in 1989 (10) and were followed by more extensive analyses
of gene mutations (14-20) and protein alteration (17,19,21-24). In studies
that have examined both p53 gene mutations and loss of heterozygosity (LOH)
on chromosome 17p, 70% of tumors with p53 mutation have corresponding loss
of chromosome 17p (15-18,20,25). Loss of an allele from a chromosome is called
LOH, and is thought to be important in the process of human tumorigenesis.
Although p53 can be inactivated at either the gene or the protein level, gene
inactivation appears to be most common mechanism in astrocytoma formation (17).
In astrocytoma, p53 gene mutation, with or without loss of the corresponding
normal 17p allele, is by far the most common mechanism for p53 dysfunction.
p53
mutations have been reported in approximately
40% of astrocytic tumors of all grades (26).
Genetic alterations of the p53 gene such as point mutations,
deletions or insertion occur in four domains which are highly conserved among
different species (27). Missense mutations in the p53 gene are the most common
(13,28). Single amino acid changes result in a mutant p53 protein with a longer
half-life allowing its accumulation to high levels with the cell nucleus (29).
In contrast, normal or wild-type p53 protein has a very short half-life (less
than 30 minutes) and therefore is present in small amounts in normal cells
(30).
The prognostic implication of p53 mutations has not yet been
defined clearly. The authors of numerous studies have attempted to address
whether the absence or presence of p53 mutations has a prognostic role in patients
with glioma. Therefore, at present, the prognostic implication of either a
p53 genetic mutation or protein expression in gliomas is uncertain.
Rapid methods currently used for the detection of p53 alterations
have been developed including serological test, genetic analysis and immunostaining
(31,32). The most widely used has been single-strand conformation polymorphism
(SSCP) evaluation (33). Most studies of the p53 gene in human astrocytomas
and glioblastomas to date have used SSCP analysis to detect mutations (18,34-39).
Recently, we have reported the frequency of the p53 gene mutations
in our Malay patients with gliomas using single strand conformation polymorphism
(SSCP) analysis and direct DNA sequencing (40-41). We have improved this technique
by developing a procedure of non-isotopic PCR-cold SSCP using the Dcode Universal
Mutation Detection System, making it rapid and suitable for screening numerous
DNA samples (40).
Loss of Heterozygosity of 10q, 9p, 17p and 13q and PTEN
gene
Loss of heterozygosity (LOH) on several loci and mutations
on PTEN tumor suppressor gene (10q23.3) occur frequently in sporadic gliomas.
Polymerase chain reaction (PCR)-LOH analysis using microsatellite markers and
single-stranded conformational polymorphism (SSCP) analysis were performed
to determine the incidence of allelic losses on chromosome 10q, 9p, 17p and
13q and mutations of exons 5, 6 and 8 of the PTEN gene in malignant gliomas. The
rationale of analyzing allelic loss is to
determine the involvement of putative
tumor suppressor genes which might contribute to
the transformation of malignant glioma.
12 of 23 (52.2%) malignant glioma cases showed allelic losses.
The highest number of cases with LOH were detected on chromosome 10q23.3 harboring
the PTEN gene. This region was reported to be frequently deleted in LOH studies
involving the q arm of chromosome 10 and fine mapping studies of the entire
chromosome (42-45). LOH was also detected on the regions 10q25.1, 10q22, 9p21
and 13q12.3. These regions have been documented to contain genes or tumor suppressor
genes involved in several carcinomas, including malignant gliomas (42,46,47-49).
Less frequent LOH was detected on chromosomes 17p13.1 whereas no allelic loss
was detected on the region 13q12.1, suggesting that these regions are not typically
involved in the progression of malignant gliomas in Malay patients.
7 of 23 (30.4%) samples showed aberrant band patterns and
mutations of the PTEN gene. Most of PTEN gene mutations detected in the present
study were anaplastic astrocytoma and glioblastoma. Five codons containing
CpG dinucleotides were found mutated on exons 5 and 6 of the PTEN gene, which
involved entirely missense and nonsense mutations. The codon most frequently
affected or mutated was codon 173 which is conserved in tensin, auxilin and
bacterial phosphatase (50). The mutations of this gene which lead to amino
acid substitutions may generally affect conserved residues or structurally
conserved features of the protein (44). It is believed that the N-terminal
half of PTEN is functionally more significant for tumor suppression because
of homology to tensin, auxilin and phosphatase, regions that may control cell
cycle, invasion and metastasis (51). These findings suggest that mutations
of PTEN are concentrated to the N-terminal phosphatase domain with cluster
of mutations in the region 5' to the core phosphatase motif and the 5'-end
of exon 6.
4 of the tumors containing PTEN mutations also showed loss
of heterozygosity in the chromosome 10q23 region flanking the PTEN gene. The
pattern of allelic losses on 10q23 as well as mutations of the gene itself
appear to be associated with the progression of glioma (52,53) and indicated
complete loss of the wild-type PTEN gene (54). These findings also suggest
that PTEN gene might be inactivated by point mutations or small deletions (52)
and that both alleles of the PTEN gene were inactivated by a classical two-hit
mechanism (55), therefore confirming the previous idea that PTEN
acts as a tumor suppressor gene.
Absence of p16 gene alterations in CNS tumours
The p16 gene is a tumour suppressor gene located at chromosome
9p21. It is also known as Major Tumor Suppressor 1 (MTS1), Inhibitor of Cyclin-dependent
4a (INK4a) and Cyclin-dependent Kinase Inhibitor 2a (CDKN2A) which consists
of 3 exons and 2 introns which encodes 156 amino acids, 15.8 kD protein (56,57).
This protein acts as a negative protein regulator and loss of its function
may lead to cancer progression by allowing unregulated cellular proliferation
(56). Alterations of p16 gene can occur via different mechanism such as homozygous
deletion, point mutation and hypermethylation of this gene in promoter region
(58).
High frequent mutations and deletions of this gene in human
cancer cell lines first suggested an important role in the occurrence of many
types of cancer. Germ-line mutations have been reported in melanomas as reported
by previous author (59). Somatic mutations also have been detected in various
types of cancer such as pancreas, esophagus, lung and brain (60-63).
Molecular analysis of p16 gene was carried out using 50 cases
of CNS tumours from Malaysian patients. We performed PCR-SSCP technique to
screen p16 gene mutation and confirmed with DNA sequencing analysis. Homozygous
deletion of this gene has been detected using multiplex-PCR method as previously
described (59). Our study indicated that there was no alteration of p16 gene
via homozygous deletion and point mutation at exon 1 and 2 in CNS tumours from
Malaysian patients and this gene might not play a major role in tumourigenesis
mainly of malignant gliomas (64).
It has been reported that deletion of p16 gene was more frequent
in high grade of gliomas (48). In most studies, investigators also have revealed
that deletion of this gene was less common in primary tumours than in cell
lines (65,66). In accordance to previous study by Jen and colleagues in 1994,
the p16 gene was often homozygously deleted in glioblastoma multiformes (GBM)
but not in medulloblastomas or ependymomas (65). It has been shown that this
gene was often mutated in GBM, but the frequency of p16 mutations was still
low. Other study reported that p16 gene mutations was a rare mechanism in astrocytic
tumours (67). It is possible that there is another mechanism of p16 inactivation
involved in the development of CNS
tumours in Malaysian patients such
as hypermethylation of this gene in the promoter region. Further studies that
involved more samples of high-grade tumours, however, should be undertaken
to determine the importance of the
role of p16 in tumourigenesis.
Telomerase activity in CNS tumours
Telomerase activity has been proposed to be valuable in the
diagnosis and prognosis of malignant tumors since this unique ribonucleoprotein
enzyme is detected in most cancer cells but do not in almost normal somatic
tissues. With every cell division, the length of the telomeres decreases due
to the end replication problem. However, this problem can be prevented by maintaining
telomeric length by telomerase. Both telomerase and telomere have been identified
as targets for anticancer therapy since there were an evidence of a strong
correlation between telomerase reactivation, cellular immortalization and cancer
(68).
In our study, telomerase activity was detected in 6 out of
23 cases of CNS tumours (26.1%) including oligodendroglioma, GBM, paraganglioma
and meduloblastoma. We also revealed that there was a significance association
between telomerase activity status with tumour grade (p<0.05). Detection
of this enzyme in analyzed tumours supports the fact that activation of telomerase
may associate with tumour progression. Our results also showed similar findings
with other studies reported that telomerase activity was detected in GBM, oligodendroglioma
and meduloblastoma (70,71). In contrast, telomerase activity was not detected
in all schwannoma and meningioma samples. Similarly it was reported by the
authors of the previous studies (69,71-73). According to previous review,
758 of 895 (85%) of malignant tumours (higher grade tumours), but none of 70
normal somatic tissues, expressed telomerase activity (74). This strong association
of telomerase activity with malignant tissue is good evidence that telomerase
can be an important marker for diagnosing cancer (74).
Telomerase activity was determined based on the PCR-Telomeric
Repeat Amplification Protocol (TRAP) assay using TRAPEZE Telomerase
Detection Kit (Intergen Co., USA) which derived from an improved version of
the original method as previously described (75). We accomplished in detecting
this telomerase activity using a non-isotopic TRAP-silver staining method.
According to the previous studies, TRAP assay combined with
silver staining method could be a common
practice for the routine laboratory because it has
been considered to be a quick, easy, safe and
cost-effective staining protocol (76-78). It has been suggested
that TRAP-silver staining assay of telomerase
activity may be used as a routine diagnostic method for
brain tumour detection in the future (79).
Conclusions
These new approaches will undoubtedly contribute to a better
understanding of carcinogenesis. Further investigations should be lead to generate
other tumour markers which can possibly be used in the future screening, early
diagnosis, staging and surveillance of cancer. An important aspect of this
review is to provide an insight into central nervous system tumours etiology
important for the development of prevention strategies.
Acknowledgements
This work was supported by grants from Yayasan FELDA (no.
304/PPSP/6150033Y104), Intensification of Research in Priority Areas (no. 304/PPSP/6131122)
and The Malaysian Japanese Toray Research Foundation Grant (no. 380/0500/5051).
References
1. Taylor, F. Brain and Spinal Cord Tumors: Hope Through
Research. Bethesda: National Institute of Neurological Disorder and Stroke
(NINDS), 1993.
2. Leon, S.P., Zhu, J., Black, P.M. Genetic aberrations in
human brain tumors. Neurosurgery 1994;34(4): 708-722.
3. Yuasa, Y. Genetic diagnosis and gene therapy for cancer. Asian
Med J 2000;43(9): 430-439.
4. Fueyo, J., Gomez-Manzano, C., Yung, W.K.A., Kyritsis, A.P.
The functional role of tumor suppressor genes in gliomas-Clues for future therapeutic
strategies. Neurology 1998;51: 1250-1255.
5. Fathallah-Shaykh, H. New molecular strategies to cure brain
tumors. Arch Neurol 1999;56(4): 449-451.
6. Shay, J.W, Gazdar, A.F. Telomerase in the early detection
of cancer. J Clin Pathol 1997;50(2): 106-108.
7. Lane, D.P., Crawford, L.V. T antigen is bound to a host
protein in SV40-transformed cell. Nature 1979;278: 261-263.
8. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B.,
Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., Vogelstein
B. Waf1, a potential mediator of p53 tumor suppression. Cell 1993;75:
817-825.
9. Karp J.E, Broder S. New directions in molecular medicine. Cancer
Res 1994;54: 653-665.
10. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl
G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification
in cells with mutant p53 alleles. Cell 1992;70: 937-948.
11. El-Deiry, W.S., Harper J.W., O'Connor P.M., Velculescu
V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang
Y., Wiman K.G., Mercer W.E., Kastan M.B., Kohn K.W., Elledge S.J., Kinzler
K.W., Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer
Res 1994;54: 1169-1174.
12. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.
M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Deville,
P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C., Vogelsteein,
B. Mutations In The P53 Gene Occur In Diverse Tumour Types. Nature 1989;342:
705-708.
13. Hollstein M., Sidransky D., Vogelstein B., Harris C.C.
P53 Mutations In Human Cancers. Science 1991;253: 49-53.
14. Chozick, B.S., Weicker, M.E., Pezzullo, J.C., Jackson,
C.L., Finkelstein, S.D., Ambler, M.W., Epstein, M.H., Finch, P.W. Pattern Of
Mutant P53 Expression In Human Astrocytomas Suggests The Existence Of Alternate
Pathways Of Tumorigenesis. Cancer 1994;73: 406-415.
15. Frankel, R.H., Bayona, W., Koslow, M., Newcomb, E.W. p53
mutations in human malignant gliomas: Comparison of loss of heterozygosity
with mutation frequency. Cancer Res 1992;52: 1427-1433.
16. Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A.,
Cawthon, R.M. p53 mutations and loss of heteroygosity on chromosomes 17 and
10 during human astrocytoma progression. Cancer Res 1992;52:
674-679.
17. Louis D.N., Von Deimling A., Chung R.Y., Rubio M.P., Whaley
J.M., Eibl R.H., Ohgaki H., Wiestler O.D., Thor A.D. & Seizinger B.R. Comparative
Study Of P53 Gene And Protein Alterations In Human Astrocytomas. J Neuropathol
Exp Neuro 1993;52: 31-38.
18. Mashiyama S., Murakami Y., Yoshimoto T., Sekiya T., Hayashi
K. Detection of p53 mutations in human brain tumors by single-strand conformation
polymorphism analysis of polymerase chain reaction
products. Oncogene 1991;6: 1313-1318.
19. Newcomb, E.W., Madonia W.J., Pisharody S., Lang F.F.,
Koslow M., Miller D.C. A Correlative Study Of P53 Protein Alteration And P53
Gene Mutation In Glioblastoma Multiforme. Brain Pathol 1993;3:
229-235.
20. von Deimling, A., Eibl, R.H., Ohgaki, H., Louis, D.N.,
von Ammon, K., Petersen, I., Kleihues, P., Chung, R.Y., Wiestler, O.D., Seizinger,
B.R. p53 mutations are associated with 17p allelic loss in grade II and grade
III astrocytoma. Cancer Res 1992;52: 2987-2990.
21. Ellison, D.W., Gatter, K.C., Steart, P.V., Lane, D.P.,
Weller, R.O. Expression of the p53 protein in a spectrum of astrocytic tumors. J
Pathol 1992;168: 383-386.
22. Haapasalo, H., Isola, J., Sallinen, P., Kalimo, H., Helin,
H., Rantala, I. Aberrant P53 Expression In Astrocytic Neoplasms Of The Brain:
Association With Proliferation. Am J Pathol 1993;142: 1347-1351.
23. Jaros, E., Perry, R.H., Adam, L., Kelly, P.J., Crawford,
P.J., Kalbag, R.M., Mendelow, A.D., Sengupta, R.P., Pearson, A.D. Prognostic
implications of p53 protein, epidermal growth factor receptor, and Ki-67 labeling
in brain tumors. Br J Cancer 1992;66: 373-385.
24. Rubio, M.P., von Deimling, A., Yandell, D.W., Wiestler,
O.D., Gusella, J.F., Louis, D.N. Accumulation of wild type p53 protein in human
astrocytomas. Cancer Res 1993;53: 3465-3467.
25. Chung, R., Whaley, J., Kley, N., Anderson, K., Louis,
D., Menon, A., Hettlich, C., Freiman, R., Hedley-Whyte, E. T., Martuza, R.,
Jenkins, R., Yandell, D., Seizinger, B. R. TP53 gene mutations and 17p deletions
in human astrocytomas. Genes Chrom Cancer 1991;3: 323-331.
26. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C.
Mutations In The P53 Tumor Suppressor Gene: Clues To Cancer Etiology And Molecular
Pathogenesis. Cancer Res 1994;54: 4855-4878.
27. Soussi T., Caron de Fromental C., May P. Structural aspect
of the p53 protein in relation to gene evolution. Oncogene 1990;5:
945-952.
28. Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor
gene. Nature 1991;351: 453-456.
29. Finlay C.A., Hinds P.W., Tan T-H, Eliyahu D., Oren M.,
Levine A.J. Activating mutations for transformation by p53 produce a gene product
that form an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:
531-539.
30. Reich N.C., Levine A.J. Growth regulation of a cellular
tumor antigen, p53, in transformed cell. Nature 1984;308: 199-201.
31. Bosari S., Viale G. The clinical significance of p53 aberrations
in human tumours. Virchows
Arch 1995;427: 229-241.
32. Chang F., Syrjanen S., Syrjanen K. Implication of the
p53 tumor suppressor gene in clinical oncology. J Clin Oncol 1993;13:
1009-1022.
33. Orita M., Suzuky Y., Sekiya T., Hayashi K. Rapid and sensitive
detection of point missense mutation and DNA polymorphisms using the polymerase
chain reaction. Genomic 1989;5: 874-879.
34. Wu J.K., Zhen Y., Darras B.T. Frequency of p53 tumor suppressor
gene mutations in human primary brain tumors. Neurosurgery 1993;33:
824-831.
35. Lang F.F., Miller D.C., Pisharody S., Koslow M., Newcomb
E.W. High Frequency Of P53 Protein Accumulation Without P53 Gene Mutation In
Human Juvenile Pilocytic, Low Grade And Anaplastic Astrocytomas. Oncogene 1994;9:
949-954.
36. Koga H., Zhang S., Kumanishi T., Washiyama K., Ichikawa
T., Tanaka R., Mukawa J. Analysis of p53 gene mutations in low- and high-grade
astrocytomas by polymerase chain reaction-assisted single-strand conformation
polymorphism and immunohistochemistry. Acta Neuropathol 1994;87:
225-232.
37. Sakar F.H., Kupsky W.J., Li Y.W., Sreepathi P. Analysis
of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand
conformation polymorphism and DNA sequencing. Diag Mol Path 1994;3:
2-8.
38. Li Y., Millikan R.C., Carozza S., Newman B., Liu E., Davis
R., Miike R., Wrensch M. P53 Mutation In Maglinant Gliomas. Cancer Epidemiol
Biomarkers Prev 1998;7(4): 303-308.
39. Tangnipon W., Mizoguchi M., Kukita Y., Inazuka M., Iwaki
T., Fukui M., Hayashi K. Distinct pattern of PCR-SSCP analysis of p53 mutation
in human astrocytomas. Cancer Lett 1999;141: 195-201.
40. Isa M.N., Yusoff A.A., Sidek M.R., Abdullah J.M. Non-isotopic
PCR-cold SSCP of p53 gene mutations in Gliomas using the Dcode System. Asia
Pacific J Mol Biol & Biotechnol 2001;9(2): 107-110.
41. Aziz M.Y., Jafri M.A., Mohd Ros S., Mohd Nizam I. Mutations
of the p53 gene in gliomas from Malay patients. The Med J Malaysia 2003;58(2):
225-232.
42. Cheng Y., Ng H., Ding M., Zhang S. Molecular analysis
of microdissected de novo glioblastomas and paired astrocytic tumors. J
Neuropathol Exp Neurol 1999;58: 120-128.
43. Fujisawa H., Reis R.M., Nakamura M., Colella S., Yonekawa
Y., Kleihues P., Ohgaki H. Loss of heterozygosity on chromosome 10 is more
extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:
65-72.
44. Schmidt E.E., Ichimura K., Goike H.M., Moshref A. Mutational
profile of the PTEN gene in primary human astrocytic tumors and cultivated
xenografts. J Neuropathol Exp Neurol 1999;58: 1170-1182.
45. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky
D., Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer
Res 1997;57: 4183-4186.
46. Schmidt E.E., Ichimura K., Reifenberger G., Collins V.P.
CDKN2 (p16/MTSI) gene deletion or CDK4 amplification occurs in the majority
of glioblastomas. Cancer Res 1994;54: 6321-6324.
47. Lee S., Kim J., Rhee C., Kang Y., Lee J., Hong S., Choi
K. Loss of heterozygosity on chromosome 10, 13q (Rb), 17p and p53 gene mutations
in human brain gliomas. J Korean Medical Sc 1995;10: 442-448.
48. Walker D.G., Duan W., Popovic E.A., Kaye A.H., Tomlinson
F.H., Lavin M. Homozygous deletions of the multiple tumor suppressor gene in
the progression of human astrocytomas. Cancer Res 1995;55: 20-23.
49. Watling C.J., van Meyel D.J., Ramsay D.A., Macdonald D.R.,
Cairncross J.G. Loss of heterozygosity analysis of chromosomes 9, 10 and 17
in gliomas in families. Can J Neurol Sc 1995;22: 17-21.
50. Ali I.U., Schriml L.M., Dean M: Mutational spectra of
PTEN/MMAC1 gene. A tumor suppressor with lipid phosphatase activity. J Natl
Cancer Inst 1999;91: 1922-1932.
51. Ishii N., Maier D., Merio A., Tada M., Sawamura Y., Diserens
A., Van Meir E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF,
PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:
469-479.
52. Ichimura K., Schmidt E.E., Miyakawa A., Goike H.M., Collins
V.P. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple
tumor suppressor genes in the development of astrocytic gliomas of different
malignancy grades. Genes Chrom Cancer 1995;22: 9-15.
53. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch
D.H., Louis D.N., Cavenee W.K. DePinho R.A. Malignant glioma: genetics and
biology of a grave matter. Genes Devel 2001;15: 1311-1333.
54. Bostrom J., Cobbers J.M., Wolter M., Tabatabai G., Weber
R.G., Lichter P., Collins V.P. & Reifenberger G. Mutation of the PTEN (MMAC1)
tumor suppressor gene in a subset of glioblastomas but not in meningiomas with
loss of chromosome arm 10q. Cancer Res 1998;58: 29-33.
55. Kato H., Kato S., Kumabe T., Sonoda Y., Yoshimoto T.,
Han S., Suzuki T., Shibata H., Kanamaru R. & Ishioka C. Functional evaluation
of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000;6:
3937-3943.
56. Liggett, W.H., Sidransky, D. Role of the p16 tumor suppressor
gene in cancer. J Clin
Oncol 1998;16(3): 1197-1206.
57. Guang, Z., Xianhou, Y. Study of deletion of P16 gene in
the progression of brain astrocytomas. Chinese J Cancer Res 1998;10:
412-417.
58. Ng, H-K. & Lam, P.Y.P. The molecular genetics of central
nervous system tumors. Pathology 1998;30: 196-202.
59. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins
P.A., Ally D.S., Sheahan M.D., Clark W.H. Jr, Tucker M.A., Dracopoli N.C. Germline
p16 mutations in familial melanomas. Nature Genet 1994;8: 15-21.
60. Caldas, C., Hahn, S.A., Dacosta, L.T., Redston, M.S.,
Schutte, M., Seymour A.B., Weinstein, C.L., Hruban, R.H., Yeo, C.J. & Kern,
S.E. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene
in pancreatic adenocarcinoma. Nature Genet 1994;8: 27-32.
61. Mori T., Miura K., Aoki T., Nishihira T., Mori S., Nakamura
Y. Frequent somatic mutation of the MTS1/CDK4 (multiple tumor suppressor/cyclin-dependent
kinase 4 inhibitor) gene in esophageal squamoous cell carcinomas. Cancer
Res 1994;54: 3396-3397.
62. Hayashi N., Sigimota Y., Tsuchiya E., Ogawa M, Nakamura
Y. Somatic mutations of the MTS1 (multiple tumor suppressor 1)/CDK4I (cyclin
dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem
Biophys Res Comm 1994;202: 1426-1430.
63. Izumoto S., Arita N., Ohnishi T., Hiraga S., Taki T. & Hayakwa
T. Homozygous deletion of p16INK4A/MTS1 and p15INK4B/MTS2
genes in glioma cells and primary glioma tissues. Cancer Lett 1995;97:
241-247.
64. Jafri Malin A., Norafiza Z., Sarina S., Hasnan J. & Mohd
Nizam I. Molecular genetic analysis of phosphatase and tensin homolog and p16
tumour suppressor genes in patients with malignant glioma. Neurosurgical
Focus 2003;14(4): Article 6.
65. Jen, J., Harper, J.W., Bigner, S.H., Bigner, D.D., Papadopoulos,
N., Markowitz, S., Willson, J.K.W., Kinzler, K.W. & Vogelstein, B. Deletion
of p16 and p15 genes in brain tumors. Cancer Res 1994;54: 6353-6358.
66. Spruck, C.H. III., Gonzalez-Zulueta, M., Shibata, A.,
Simoneau, A.R., Lin, M-F., Gonzales, F., Tsai, Y.C. & Jones, P.A. p16 gene
in uncultured tumours. Nature 1994;370: 183-184.
67. Schmidt, E.E., Ichimura, K., Messerle, K.R., Goike, H.M. & Collins,
V.P. Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both
CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997;75(1):
2-8.
68. Urquidi V, Tarin D, Goodison S. Role of telomerase in
cell senescence and oncogenesis. Annu Rev Med 2000;51: 65-70.
69. Falchetti, M.L., Pallini, R., Larocca, L.M., Verna,
R. & D'Ambrosio, E. Telomerase expression in intracranial tumours: Prognostic
potential
for malignant gliomas and meningiomas. J Clin
Pathol 1999;53(2): 234-236.
70. Sano, T., Asai, A., Mishima, K., Fujimaki, T. & Kirino,
T. Telomerase activity in 144 brain tumours. Br J Cancer 1998;77(10):
1633-1637.
71. Chen, H-J., Cho, C-L., Liang, C-L., Chen, L., Chang, H-W.,
Lu, K. & Lee, T-C. Differential telomerase expression and telomere length
in primary intracranial tumors. The Chang Gung Med J 2001;24(6):
352-359.
72. Hiraga, S., Ohnishi, T., Izumoto, S., Miyahara, E., Kanemura,
Y., Matsumura, H. & Arita, N. Telomerase activity and alterations in telomere
length in human brain tumors. Cancer Res 1998;58: 2117-2125.
73. Langford, L.A., Piatyszek, M.A., Xu, R., Schold, S.C.,
Wright, W.E., & Shay, J.W. Telomerase activity in ordinary meningiomas
predicts poor outcome. Hum Pathol 1997;28(4): 416-420.
74. Kim, N.W. Clinical implication of telomerase in cancer. Eur
J Cancer 1997;33(5): 781-786.
75. Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B.,
West, M.D., Ho, L.C., Coviello, G.M., Wright, W.E., Weinrich, S.L. & Shay,
J.W. Specific association of human telomerase activity with immortal cells
and cancer. Science 1994;266: 2011-2015.
76. Wen, J.M., Sun, L.B., Zhang, M. & Zheng, M.H. A non-isotopic
method for the detection activity in tumour tissues: TRAP-silver staining assay. J
Clin Pathol 1998;51(2): 110-113.
77. Dalla Torre, C.A., Maciel, R.M.B., Pinheiro, N.A., Andrade,
J.A.D., de Toledo, S.R.C., Villa, L.L. & Cerutti, J.M. TRAP-silver staining,
a highly sensitive assay for measuring telomerase activity in tumor tissue
and cell lines. Brazillian J Med Biol Res 2002;35: 65-68.
78. Fujita, M., Tomita, S., Ueda, Y., Fujimori, T. & Zheng,
M-H. Gel staining methods for detection of telomerase activity with the telomeric
repeat amplification protocol (TRAP) assay/Reply. J Clin Pathol 1998;51:
342-343.
79. Sarina S., Jafri Malin A., Mohamad Ros S., Jain George
P. & Mohd Nizam I. A non-isotopic method for the detection of telomerase
activity in human brain tumours: TRAP-Silver staining assay. Malaysian J
Biochem and Mol Biol 2003;8: 45-48.
Copyright 2004 - Malaysian Journal of Medical Sciences
|